Cardiovascular Systems (CSII) Stock Forecast, Price & News

Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions

Is Cardiovascular Systems a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Cardiovascular Systems stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CSII, but not buy additional shares or sell existing shares.
View analyst ratings for Cardiovascular Systems or view top-rated stocks.

When is Cardiovascular Systems' next earnings date?

Cardiovascular Systems is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Cardiovascular Systems.

How were Cardiovascular Systems' earnings last quarter?

Cardiovascular Systems, Inc. (NASDAQ:CSII) issued its earnings results on Wednesday, May, 4th. The medical device company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.03. The medical device company earned $56.22 million during the quarter, compared to the consensus estimate of $57.38 million. Cardiovascular Systems had a negative trailing twelve-month return on equity of 12.43% and a negative net margin of 13.29%. Cardiovascular Systems's quarterly revenue was down 11.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.15) EPS.
View Cardiovascular Systems' earnings history.

What guidance has Cardiovascular Systems issued on next quarter's earnings?

Cardiovascular Systems updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $235.00 million-$240.00 million, compared to the consensus revenue estimate of $237.88 million.

What price target have analysts set for CSII?

7 equities research analysts have issued 12-month price objectives for Cardiovascular Systems' stock. Their forecasts range from $20.00 to $49.00. On average, they anticipate Cardiovascular Systems' stock price to reach $39.40 in the next twelve months. This suggests a possible upside of 145.2% from the stock's current price.
View analysts' price targets for Cardiovascular Systems or view top-rated stocks among Wall Street analysts.

Who are Cardiovascular Systems' key executives?

Cardiovascular Systems' management team includes the following people:

• Mr. Scott Raymond Ward B.Sc., M.S., MS, Chairman, Pres & CEO (Age 62, Pay $1.46M)
• Mr. Jeffrey S. Points, Chief Financial Officer (Age 45, Pay $682.69k) (LinkedIn Profile)
• Ms. Rhonda J. Robb, Chief Operating Officer (Age 54, Pay $954.83k) (LinkedIn Profile)
• Mr. Alexander Rosenstein, Gen. Counsel & Corp. Sec. (Age 50, Pay $614.96k)
• Mr. John M. Hastings, Exec. VP of Operations & Technology (Age 42)
• Mr. John E. Nielsen, VP of Investor Relations & Corp. Communications
• Ms. Sandra M. Sedo, Chief Compliance Officer (Age 58)
• Mr. David S. Whitescarver, VP of Corp. Devel. & Intellectual Property (Age 64)
• Mr. Stephen J. Rempe, Chief HR Officer (Age 49)
• Dr. Jeffrey W. Chambers M.D., Chief Medical Officer

What is Scott Ward's approval rating as Cardiovascular Systems' CEO?

12 employees have rated Cardiovascular Systems CEO Scott Ward on Glassdoor.com. Scott Ward has an approval rating of 81% among Cardiovascular Systems' employees.

Who are some of Cardiovascular Systems' key competitors?

Some companies that are related to Cardiovascular Systems include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX).
View all of CSII's competitors.

What other stocks do shareholders of Cardiovascular Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include Gilead Sciences (GILD), AbbVie (ABBV), Advanced Micro Devices (AMD), Medtronic (MDT), Pfizer (PFE), Xcel Energy (XEL), ACADIA Pharmaceuticals (ACAD), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Procter & Gamble (PG).

What is Cardiovascular Systems' stock symbol?

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Who are Cardiovascular Systems' major shareholders?

Cardiovascular Systems' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (17.38%), Champlain Investment Partners LLC (8.55%), Vanguard Group Inc. (6.35%), State Street Corp (4.22%), Renaissance Technologies LLC (2.09%) and Neuberger Berman Group LLC (1.98%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Erik Paulsen, Jeffrey S Points, Martha Goldberg Aronson, Rhonda J Robb, Sandra Sedo and Scott R Ward.
View institutional ownership trends for Cardiovascular Systems.

Which major investors are selling Cardiovascular Systems stock?

CSII stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Engineers Gate Manager LP, JPMorgan Chase & Co., Vanguard Group Inc., Assenagon Asset Management S.A., Exchange Traded Concepts LLC, Walleye Capital LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Cardiovascular Systems or view top insider-selling stocks.

Which major investors are buying Cardiovascular Systems stock?

CSII stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Royal Bank of Canada, BlackRock Inc., Neuberger Berman Group LLC, GSA Capital Partners LLP, White Pine Capital LLC, Envestnet Asset Management Inc., and M&T Bank Corp. Company insiders that have bought Cardiovascular Systems stock in the last two years include Erik Paulsen, Jeffrey S Points, Martha Goldberg Aronson, Rhonda J Robb, and Scott R Ward.
View insider buying and selling activity for Cardiovascular Systems or or view top insider-buying stocks.

How do I buy shares of Cardiovascular Systems?

Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiovascular Systems' stock price today?

One share of CSII stock can currently be purchased for approximately $16.07.

How much money does Cardiovascular Systems make?

Cardiovascular Systems has a market capitalization of $655.41 million and generates $258.97 million in revenue each year. The medical device company earns $-13.42 million in net income (profit) each year or ($0.840010) on an earnings per share basis.

How many employees does Cardiovascular Systems have?

Cardiovascular Systems employs 780 workers across the globe.

When was Cardiovascular Systems founded?

Cardiovascular Systems was founded in 1989.

What is Cardiovascular Systems' official website?

The official website for Cardiovascular Systems is www.csi360.com.

How can I contact Cardiovascular Systems?

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at (651) 259-1600, via email at [email protected], or via fax at 612-677-3355.